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Sarah McAvoy,1 K. Scott Baker,2 Daniel Mulrooney,3 Anne Blaes,4 Mukta Arora,1,4
Linda J. Burns,1,4 Navneet S. Majhail1,4Exposure to corticosteroids increases the risks of avascular necrosis (AVN) of the bone after hematopoietic cell
transplantation (HCT). However, whether this effect is dependent on the dose of corticosteroids is not well
known. We conducted a case-controlled study, which included 74 recipients of autologous or allogeneic
HCTwith AVN and 147 controls without AVN that werematched by age, sex, and year of HCT to cases. Cases
withAVN included 8 autologousHCTrecipients, 58myeloablative allogeneicHCTrecipients, and 8 recipients of
nonmyeloabalative allogeneicHCT.Corticosteroid exposurewas expressed as cumulative doses of prednisone.
Cases received higher cumulative doses of prednisone than controls, and among allogeneic HCT recipients,
cases were more likely to have developed acute and chronic graft-versus-host disease (aGVHD, cGVHD). Cu-
mulative doseof prednisonewas an independent risk factor forAVN.Compared tonocorticosteroid exposure,
exposure to\3870 mg cumulative dose of prednisone was associated with 4.0 (95% confidence intervals, 1.5-
11.2) times higher risk, 3870-9735mgwith 5.6 (2.1-15.2) times higher risk and.9735with 8.6 (3.2-23.5) times
higher risk of AVN. Exposure to higher doses of corticosteroids increases the risk of AVN in HCTrecipients.
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Improvements in transplantation techniques and
supportive care have led to an increasing number of
hematopoietic cell transplant (HCT) survivors. These
survivors are at risk of late complications because of
HCT-related exposures including conditioning-
regimen chemotherapy and irradiation, immunosup-
pressive drugs, and graft-versus-host disease (GVHD)
[1-6]. Avascular necrosis (AVN) of the bone is 1 such
late complication that occurs because of disruption of
blood supply to the bone with resultant death of the1Blood and Marrow Transplant Program, University of
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6/j.bbmt.2010.03.008bone and collapse of bone structure. AVN has been
described in 4% to 19% of HCT survivors and can
lead to joint pain, bone destruction, and loss of
function with significant impairment in quality of life
[7-14]. Up to 48% of affected patients require joint
replacement surgery [8,9,11].
Putative risk factors for posttransplant AVN in-
clude female sex, older age, allogeneic donor source,
acute and chronic GVHD (aGVHD, cGVHD), corti-
costeroid therapy, and total body irradiation (TBI)
[7-9,11,13,15-17]. Recently, exposure to calcineurin
inhibitors and mycophenolate mofetil have been
implicated as risk factors for development of AVN
[13]. The effect of corticosteroid dose on AVN risk
has not been previously described.We conducted a sin-
gle institution case-controlled study to determine the
association between cumulative doses of corticoste-
roids and risk of AVN. We also describe the clinical
presentation of AVN in our patient cohort and exam-
ine other important risk factors for post-HCT AVN.METHODS
Patients
The University of Minnesota Blood and Marrow
Transplant program’s database, which prospectively1231
Table 1. Characteristics of Cases and Controls
Characteristic Cases Controls P-Value
N 74 147
Age, years —*
Median (range) 28 (4-60) 28 (4-60)
Sex —*
Male 46 (62%) 95 (64%)
Female 28 (38%) 52 (36%)
Diagnosis .12
Acute leukemia 36 (49%) 49 (33%)
Chronic myelogenous leukemia 15 (20%) 30 (20%)
Lymphoma 12 (16%) 32 (22%)
Nonmalignant disorder 8 (11%) 18 (12%)
Other 3 (4%) 18 (12%)
Previous transplant 0 11 (8%) .02
Transplant type .04
Allogeneic myeloablative 58 (78%) 93 (63%)
Allogeneic nonmyeloablative 8 (11%) 17 (12%)
Autologous 8 (11%) 37 (25%)
Total-body irradiation dose .62
No total-body irradiation 15 (20%) 38 (26%)
200 cGy 8 (11%) 17 (12%)
1320 cGy 51 (69%) 92 (62%)
Acute GVHD
(allogeneic HCTonly)
<.01
No 14 (21%) 49 (44%)
Yes 52 (79%) 61 (56%)
Chronic GVHD
(allogeneic HCTonly)
<.01
No 17 (26%) 73 (66%)
Yes 49 (74%) 37 (34%)
Prednisone cumulative
dose, mg†
.05
Median (interquartile range) 7043
(2352-12,755)
1800
(0-7895)
Prednisone cumulative
dose, mg†,‡
<.01
No prednisone exposure 6 (8%) 50 (34%)
<3,870 18 (24%) 37 (25%)
3,870-9,735 22 (30%) 33 (23%)
>9,735 28 (38%) 27 (18%)
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell
transplantation.
*Cases and controls were matched by age, sex, and year of transplanta-
tion.
†Prednisone equivalent dose of other corticosteroids.
‡Cumulative prednisone dose for cases and controls categorized by
tertiles.
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post-HCT outcomes, was queried for AVN of the
bone as a post-HCT complication. Patients were eligi-
ble for our study if they had received an allogeneic or
autologous HCT between 1990 and 2007. All age
groups, diagnoses, and donor sources were considered
for our study. Medical charts of patients with AVN
were reviewed to obtain more information about
AVNdiagnosis, risk factors, and treatment. To be clas-
sified as an AVN case, patients were required to have
computed tomography (CT) or magnetic resonance
imaging (MRI) evidence of AVN or had undergone
joint arthroplasty or another surgical procedure for
AVN.
Eighty-four cases of AVN were reported among
3786 patients (autologous 5 1157, allogeneic 5
2629). From these, 10 patients were excluded; 6 pa-
tients did not meet our case definition for AVN (lack
of radiological evidence of AVN) and the diagnosis
of AVN preceded HCT in 4 patients. Hence, our final
cohort of cases consisted of 74 patients (Table 1).
Controls
Two controls were randomly selected for each case
from the same cohort of 3786 patients and were
matched to cases by age (65 years), sex, and year of
transplantation (61 year). We did not match cases
and controls by transplant type because we wanted to
evaluate this variable as a risk factor for AVN. Medical
records of controls were reviewed to ascertain absence
of AVN or other bone complications. In addition, con-
trols with any documented history of bone and joint
related symptoms were excluded.
Risk Factors
The primary objective of this study was to evaluate
cumulative dose of corticosteroids as a risk factor for
AVN. The following additional risk factors for AVN
were also considered a priori: (1) diagnosis (acute leuke-
mia versus chronic myelogenous leukemia versus lym-
phoma versus nonmalignant disorders), (2) transplant
type (autologous versus allogeneic), (3) TBI use (yes
versus no), and (4) history of previous transplantation.
Corticosteroid dose was abstracted from a detailed
review of medical charts for both cases and controls.
For the purposes of this study, corticosteroid dose is
presented as prednisone dose in ‘‘mg.’’ Dose of other
corticosteroids, if used, was converted to an equivalent
dose of prednisone. Data on corticosteroid exposure
was obtained from the date of diagnosis of hematologic
disorder to the date of onset of AVN. Hence, these in-
cluded use of corticosteroids as part of initial or salvage
therapy for the underlying hematologic disorder (eg,
prednisone in CHOP chemotherapy regimen for
non-Hodgkin lymphomas). For controls, similar data
was collected from the time of diagnosis. However,the duration of corticosteroid exposure for controls
was considered from the date of transplantation to
the date of onset of AVN in its corresponding matched
case. Because data on dose of corticosteroids was re-
corded retrospectively, assumptions about dose were
made where there were gaps between reports of corti-
costeroid use (eg, in between follow-up visits). If the
dose on follow-up visit was unchanged, then the dose
during the gap was assumed to be the same. If the
dose on follow-up visit was lower or higher than previ-
ous reported dose, medical records were reviewed for
information about a dose taper or increase schedule,
which was then used to estimate the corticosteroid
dose during that time period.
We could not evaluate duration of corticosteroid
exposure as a risk factor for AVN because this was
highly correlated with cumulative corticosteroid
dose. Similarly, aGVHD and cGVHD were closely
Figure 1. Corticosteroid exposure of cases and controls by transplant type. The height of the columns represents proportion of patients within each
category. Corticosteroid exposure is presented as cumulative dose of prednisone.
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latter was considered in the risk factor analysis.
Exposure to calcineurin inhibitors also could not be
evaluated as a risk factor because all allogeneic HCT
recipients received cyclosporine as part of GVHD
prophylaxis regimen.
Statistical Analysis
Cases and controlswere compared using either chi-
square or Fisher’s tests, as appropriate, for categoric
variables and Wilcoxon rank sum test for continuous
variables. Multivariable conditional logistic regression
was used to identify risk factors that were significantly
and independently associated with AVN of bone after
HCT. Because our main objective was to explore the
effect of corticosteroid dose on the risk of AVN, we
compiled data from both cases and controls to
categorize cumulative corticosteroid dose (as mg of
prednisone) into tertiles. Hence, 4 categories for corti-
costeroid exposure were considered in multivariate
analysis if sample size permitted: no exposure, cumula-
tive prednisone dose in the lower third (\3870 mg),
cumulative prednisone dose in the middle third
(3870-9735 mg), and cumulative prednisone dose in
the upper third (.9735 mg). Statistical analyses were
performed using SAS 9.1 (SAS Institute, Cary, NC).RESULTS
Patients
Seventy-four cases and 147 controls were included
in our study (Table 1). A greater proportion of controls
had received an autologous transplant and had under-
gone previous transplantation. Cases received higher
cumulative doses of corticosteroids than controls,
and among allogeneic HCT recipients, cases weremore likely to have developed aGVHD and cGVHD.
Figure 1 describes the distribution of autologous and
allogeneic HCT recipients by corticosteroid exposure.
Compared to cases, a greater proportion of controls
had no exposure to corticosteroids. Also, a larger pro-
portion of cases received higher cumulative doses of
corticosteroids compared to controls (cumulative
prednisone dose in the highest tertile: 39% versus
23% for allogeneic HCT recipients and 25% versus
5% for autologous HCT recipients). However, corti-
costeroid exposure did not differ by age at transplanta-
tion, and the cumulative doses of prednisone among
cases and controls were comparable across age groups.
For cases, median prednisone dose was 6831 mg
among patients\18 years, 6575 mg among patients
18 to 45 years and 7875 mg for patients .45 years of
age at HCT. The median prednisone dose for controls
in the 3 age groups was 1050 mg, 2460 mg, and 1061
mg, respectively.Avascular Necrosis
Table 2 describes the characteristics of cases with
AVN of the bone. The overall cumulative incidence
of AVN at 5-years post-HCT was 3% (95% confi-
dence intervals [CI], 2%-4%) and included 8 autolo-
gous HCT recipients, 58 recipients of myeloabalative
allogeneic HCT, and 8 recipients of nonmyeloabala-
tive allogeneic HCT. The median age at onset of
AVN was 28 (range: 4-60) years and 23% of cases
occurred in children (aged\18 years). AVN occurred
at a median of 16 (range: 2-80) months after HCT, and
it occurred within 2 years of transplantation in 64% of
cases. AVN involved a total of 156 joints in these 74
patients (median number of joints involved 2 [range:
1-6]). Proximal femur (54%) and distal femur (36%)
were the most common sites of involvement.
Table 2. Characteristics of Patients with Avascular Necrosis of Bone by Transplant Type
Characteristic Autologous HCT Myeloablative Allogeneic HCT Nonmyeloablative Allogeneic HCT
N 8 58 8
Time from HCT to AVN, months
Median (range) 21 (1-80) 17 (2-76) 15 (4-41)
Age, years
Median (range) 26 (14-57) 25 (4-54) 55 (29-60)
Year of HCT
1990-1999 4 (50%) 42 (72%) 1 (13%)
2000-2007 4 (50%) 16 (28%) 7 (87%)
Diagnosis
Acute leukemia 2 (25%) 30 (52%) 4 (50%)
Chronic myeloid leukemia 0 15 (26%) 0
Lymphoma 4 (50%) 4 (7%) 4 (50%)
Nonmalignant disorder 0 8 (14%) 0
Other 2 (25%) 1 (2%) 0
Previous transplant 0 0 0
Donor type
Related — 28 (48%) 2 (25%)
Unrelated — 22 (38%) 0
Umbilical cord blood — 8 (14%) 6 (75%)
Conditioning regimen
Cy + TBI (1320 cGy) 6 (75%) 46 (79%) 0
Cy + Flu + TBI (200 cGy) 0 0 7 (87%)
Other 2 (25%) 12 (21%) 1 (13%)
Total-body irradiation*
No 6 (75%) 9 (16%) 0
Yes 2 (25%) 49 (84%) 8 (100%)
Acute GVHD
No — 12 (21%) 2 (25%)
Yes — 46 (79%) 6 (75%)
Chronic GVHD
No — 16 (28%) 3 (38%)
Yes — 42 (72%) 5 (62%)
Corticosteroid exposure
No 3 (38%) 3 (5%) 0
Yes 5 (62%) 55 (95%) 8 (100%)
Prednisone cumulative dose, mg†
Median (interquartile range) 1266 (0-0-6953) 7,460 (3398-13,883) 7,350 (2854-9322)
HCT indicates hematopoietic cell transplantation; AVN, avascular necrosis of bone; Cy, cyclophosphamide; Flu, fludarabine; TBI, total body irradiation;
GVHD, graft-versus-host disease.
*Total-body irradiation dose for myeloablative regimens was 1320 cGy given as twice daily fractions over 4 days and for nonmyeloablative regimens was
200 cGy given as a single dose.
†Prednisone equivalent dose of other corticosteroids.
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which classifies progressively worsening radiologic
abnormalities and amount of bone involvement from
stage 0 to 4, could be assigned for 52 cases; of these,
stage 3 or 4 (that requires surgical intervention) was
present in 60%. Thirty-five (48%) required surgical
treatment for AVN, among which joint replacement
was performed in 31 patients.
We also compared the characteristics of patients
who developed AVN within 1 year of HCT (N 5 28)
with those who developed it at 1 year or later
(N5 48). The age at diagnosis, sex, year ofHCT, diag-
nosis, transplant type, TBI dose, prevalence of
aGVHD and cGVHD and exposure to corticosteroids
were comparable between the 2 groups.
Six patients with no previous corticosteroid expo-
sure developed AVN. These included 2 patients each
with chronic myelogenous leukemia, acute myeloge-
nous leukemia, and Hodgkin lymphoma. Three pa-
tients had received a myeloabalative allogeneic HCTand the other 3 received an autologousHCT. Four pa-
tients had received TBI-based conditioning regimens.
Risk Factors
On multivariate analysis, corticosteroid exposure
was independently associated with the risk of develop-
ing AVN after both autologous and allogeneic HCT
(Table 3). Increasing cumulative dose of corticoste-
roids incrementally increased the risks of AVN in all
patients and in allogeneic HCT patients. An adequate
number of events were not available to investigate the
effect of corticosteroid dose in the subgroup of autolo-
gous HCT recipients. For the whole cohort, 51% of
patients with prednisone dose in the highest tertile de-
veloped AVN, compared to 40% in patients with pred-
nisone dose in the intermediate tertile, 33% in patients
with prednisone dose in the lowest tertile, and 11%
among patients who had no exposure to prednisone.
In addition to corticosteroid exposure, the only
other independent risk factor for AVN was allogeneic
Table 3. Multivariate Analysis for Corticosteroid Exposure as
a Risk Factor for Avascular Necrosis of Bone after Hemato-
poietic Cell Transplantation
Variable* Odds Ratio (95% CI) P-Value
All patients (N 5 221)
Prednisone cumulative dose, mg† <.01
No prednisone exposure 1.0
<3870 4.0 (1.5-11.2)
3870-9735 5.6 (2.1-15.2)
>9735 8.6 (3.2-23.5)
Allogeneic HCT (N 5 176)
Prednisone cumulative dose, mg† <.01
No prednisone exposure 1.0
<3870 3.4 (0.9-13.1)
3870-9735 4.7 (1.3-17.9)
>9735 7.3 (2.0-27.5)
Autologous HCT (N 5 45)‡
Exposure to prednisone .03
No 1.0
Yes (any dose) 6.0 (1.2-30.9)
HCT indicates hematopoietic cell transplantation; CI, confidence inter-
val.
*Adjusted for diagnosis, transplant type, total body irradiation, and pre-
vious transplant.
†Prednisone equivalent dose of other corticosteroids.
‡Sample size insufficient to explore cumulative dose of prednisone as
a risk factor.
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Diagnosis, use of TBI in conditioning, or prior trans-
plantation did not increase the risks of AVN.DISCUSSION
Our study highlights the importance of corticoste-
roid dose as a risk factor for AVN of the bone among
HCT recipients. AVN is a debilitating complication
of HCT, and early detection and treatment of AVN
can alleviate its morbidity. However, screening for
AVN would require periodic radiologic imaging
studies such as CT or MRI scans, and such an ap-
proachmay not be feasible or cost effective for applica-
tion among all HCT recipients or among all HCT
recipients on corticosteroid therapy. Our findings in-
dicate that a subgroup of patients who receive very
high doses of corticosteroids have the highest risk for
developing AVN, and may be candidates for further
investigations, including screening and early treatment
strategies.
Systemic corticosteroids have been implicated in
the development of AVN, but the etiology is not well
defined. Animal studies have provided some crucial in-
sights. Weinstein et al. [19] demonstrated that mice
given high doses of prensisolone have increased osteo-
blast apoptosis as well as osteoclast apoptosis leading
to decreased bone density. Wang et al. [20] showed
that steroids in rabbits produce fat degeneration,
necrosis of osteocytes, and fat embolism in the micro-
vasculature of the femoral head. In other studies,rabbits treated with methylprednisolone for 6 weeks
had decreased blood flow to the femoral head based
on perfusion studies [21].
In HCT survivors, exposure to corticosteroids is
a well-established risk factor for the development of
AVN [8,11,13,15,16]. However, corticosteroid dose
has not been well investigated as a risk factor. In
1977, Cruess [22] described detailed clinical and path-
ological characteristics of AVN in 95 patients who had
received corticosteroids for indications other than
HCT and underwent a surgical procedure for AVN.
Their cohort included 68 solid organ transplant recip-
ients. In an analysis limited to solid-organ transplant
recipients, the mean total dose (6 standard error) of
prednisone was 27.3 6 11.2 g in patients without
AVN, 32.6 6 9.1 g in patients with AVN but without
subchondral collapse, and 42.3 6 14.5 g in patients
with AVN and subchondral collapse. Fink et al. [12]
have described a case-controlled study among autolo-
gous and allogeneic HCT recipients, which included
87 cases of AVN and their age, sex, and transplant
year matched controls. After adjusting for TBI,
aGVHD or cGVHD and type of transplant, exposure
to corticosteroids was associated with a 14-fold in-
crease in risk of AVN. This risk was somewhat higher
among current users than in past users. Any duration of
corticosteroid use increased the risk of AVN, although
longer duration of exposure (\26 weeks versus 26
weeks to 1 year versus.1 year) did not cause an incre-
mental increase in this risk. They did not evaluate the
effect of corticosteroid dose in their study. In a more
contemporary prospective cohort study of 207 autolo-
gous and allogeneic HCT recipients reported by
Tauchmanova et al. [15], AVN occurred in 12 patients.
In univariate analyses that were not adjusted for other
important risk factors, AVN developed in a signifi-
cantly greater proportion of patients who received
higher cumulative doses of corticosteroids ($6 g)
and had a longer duration of exposure to corticoste-
roids (.216 days). In summary, these previous studies
and our present analysis suggest that the risk associated
with corticosteroid exposure is cumulative, and is
related to both the dose and duration of treatment.
From the perspective of investigating screening
strategies for AVN, the definition of ‘‘high-dose corti-
costeroids’’ needs to be explored further. The cate-
gories used in our study were based on tertiles of the
prednisone dose observed in our cohort (\3870 mg,
3870-9735 mg, and .9735 mg). Prednisone dose (or
equivalent dose of another corticosteroid) of 0.5 mg/
kg/day for 1 year in an adult weighing 60 kg (cumula-
tive dose 11,000 mg) corresponds to the highest
tertile dose of corticosteroids in our cohort. However,
patients who had received a lower dose of corticoste-
roids were also at increased risk of AVN. In addition
to dose, the duration of exposure to corticosteroids
may also be important. Studies need to explore
1236 Biol Blood Marrow Transplant 16:1231-1236, 2010S. McAvoy et al.whether risks of AVN with a higher dose but short du-
ration, or conversely, lower dose but longer duration
of corticosteroid exposure are any different. Because
dose highly correlated with duration of exposure in
our study, we could not consider duration of cortico-
steroid exposure as a risk factor in our analysis.
Our study does have some limitations. Although
we accounted for corticosteroid exposure as part of
initial or salvage therapy, we did not include cortico-
steroid use as part of the antiemetic regimens in
estimating cumulative corticosteroid exposure. How-
ever, antiemetic regimens typically contain relatively
small doses and use short duration of corticosteroids.
Very long-term HCT survivors without GVHD may
not be followed by our transplant program, and we
were not able to include patients without GVHD
who may have developed AVN since discharge from
our program. The characteristics of patients identified
retrospectively versus on prospective monitoring may
differ. Furthermore, although we did use control pa-
tients who did not have any documented joint symp-
toms, they did undergo imaging studies to definitely
rule out AVN. Finally, given the characteristics of
our cohort, we could not account for other recognized
risk factors for AVN such as use of calcineurin inhibi-
tors and duration of corticosteroid exposure.
In conclusion, AVN is a debilitating complication
of HCT, and often requires surgical intervention for
management of symptoms. Exposure to higher doses
of corticosteroids increases its risk. As more informa-
tion becomes available on risk factors and the patho-
genesis of this disease, we may be able to target HCT
recipients at higher risk for developing AVN for close
monitoring and early and timely interventions.ACKNOWLEDGMENTS
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